1. El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011; 365:1118–1127. PMID:
21992124.
Article
2. Arrieta O, Cacho B, Morales-Espinosa D, Ruelas-Villavicencio A, Flores-Estrada D, Hernández-Pedro N. The progressive elevation of alpha fetoprotein for the diagnosis of hepatocellular carcinoma in patients with liver cirrhosis. BMC Cancer. 2007; 7:28. PMID:
17288606.
Article
3. Kim YJ, Jang BK, Kim ES, Chung WJ, Park KS, Cho KB, et al. Hepatocellular carcinoma in the elderly: clinical characteristics, treatment, survival analysis in Korean patients older than 70 years. J Korean Med Sci. 2012; 27:1147–1154. PMID:
23091310.
Article
4. Merani S, Majno P, Kneteman NM, Berney T, Morel P, Mentha G, et al. The impact of waiting list alpha-fetoprotein changes on the outcome of liver transplant for hepatocellular carcinoma. J Hepatol. 2011; 55:814–819. PMID:
21334400.
Article
5. Tyson GL, Duan Z, Kramer JR, Davila JA, Richardson PA, El-Serag HB. Level of -fetoprotein predicts mortality among patients with hepatitis C-related hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2011; 9:989–994. PMID:
21820396.
Article